Published in Cancer Weekly, September 7th, 2004
"Trastuzumab (Herceptin) is a humanized monoclonal antibody that specifically targets HER2-positive breast cancer cells," scientists in Switzerland explained. "Safety data collected from pivotal trials with trastuzumab indicate that this therapy is generally well tolerated."
"However, trials of the combination of trastuzumab plus chemotherapy, and in particular chemotherapy with anthracyclines, have revealed an elevated incidence of cardiotoxicity in some patients, which was not apparent in preclinical or early clinical studies," noted T.M. Suter and colleagues at...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.